5.17
-0.20 (-3.72%)
| Previous Close | 5.37 |
| Open | 5.36 |
| Volume | 1,440,708 |
| Avg. Volume (3M) | 1,918,817 |
| Market Cap | 919,547,072 |
| Price / Sales | 269.28 |
| Price / Book | 4.56 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -7,273.06% |
| Diluted EPS (TTM) | -0.400 |
| Total Debt/Equity (MRQ) | 5.79% |
| Current Ratio (MRQ) | 8.33 |
| Operating Cash Flow (TTM) | -44.17 M |
| Levered Free Cash Flow (TTM) | -25.01 M |
| Return on Assets (TTM) | -26.41% |
| Return on Equity (TTM) | -41.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Compass Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.16% |
| % Held by Institutions | 67.95% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (D. Boral Capital, 480.27%) | Buy |
| Median | 10.00 (93.42%) | |
| Low | 10.00 (Canaccord Genuity, 93.42%) | Buy |
| 10.00 (Citizens, 93.42%) | Buy | |
| Average | 16.67 (222.44%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 5.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 06 Jan 2026 | 30.00 (480.27%) | Buy | 4.91 |
| 05 Nov 2025 | 30.00 (480.27%) | Buy | 3.82 | |
| Canaccord Genuity | 03 Dec 2025 | 10.00 (93.42%) | Buy | 5.28 |
| Citizens | 03 Dec 2025 | 10.00 (93.42%) | Buy | 5.28 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Jan 2026 | Announcement | Compass Therapeutics Provides Corporate Update |
| 05 Jan 2026 | Announcement | Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Jan 2026 | Announcement | Compass Therapeutics Announces Key Leadership Appointments |
| 17 Dec 2025 | Announcement | Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference |
| 25 Nov 2025 | Announcement | Compass Therapeutics to Participate in Upcoming December Investor Events |
| 05 Nov 2025 | Announcement | Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 04 Nov 2025 | Announcement | Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting |
| 03 Nov 2025 | Announcement | Compass Therapeutics to Participate in Upcoming November Investor Events |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |